SUMMARY Continuous oral dimethylsulphoxide (DMSO) treatment (7-15 g/day) was given to 3 patients with amyloidosis of familial Mediterranean fever (FMF), 3 patients with idiopathic amyloidosis, and 7 patients with secondary amyloidosis. The nephrotic syndrome and various degrees of renal insufficiency were the major clinical manifestation in all cases. Renal function was used as the main parameter for evaluation of therapy. DMSO treatment for 7-16 months produced no effect in the FMF patients and in the patients with idiopathic amyloidosis; they all ran the predictable clinical course of their disease and either died of cardiac failure or have been maintained on chronic haemodialysis. In the 7 patients with secondary amyloidosis an unequivocal improvement of renal function was observed following 3-6 months of DMSO treatment. It was shown by a 30-100 % rise of creatinine clearance and a decline in proteinuria. This new equilibrium has been maintained as long as DMSO was administered. No serious side effects of DMSO were encountered. Mild nausea and an unpleasant breath odour were the patients' main concern. We conclude that a therapeutic trial with oral DMSO is warranted in all patients with secondary amyloidosis. This treatment is unpleasant but bears no exceptional risks. It may significantly prolong life, though its effects on amyloid deposits themselves is doubtful.
Systemic amyloidosis is almost invariably fatal. Survival from the time of diagnosis ranges from several months in myeloma-associated amyloidosis to several years in secondary amyloidosis. Sporadic cases of regression of amyloidosis were reported to follow the eradication of a chronic inflammatory disease.' In some patients with stable rheumatoid arthritis the degree of renal damage may remain constant for many years.2 Usually, however, amyloidosis runs a fairly predictable downhill course. Death usually results from end-stage renal failure or cardiac disease.
Continuous colchicine administration prevents the development of amyloidosis in familial Mediterranean fever and may also arrest the progress of an already existing disease when instituted at an early stage as long as renal function is normal.34 Rarely myeloma-associated amyloidosis was reported to respond to cytotoxic agents.5 More often, however, the progress of amyloidosis is unaffected.6 For the Accepted for publication 20 October 1981. Correspondence to Dr M Ravid, Department of Medicine, Meir Hospital, Kfar Saba 44 281, Israel. majority of patients with early amyloidosis and for all patients with advanced disease no cure is as yet available. Dimethyl sulphoxide (DMSO), an industrial solvent first introduced into the treatment of amyloidosis by Isobe and Osserman,7 causes partial or total disappearance of experimentally induced amyloid deposits in mice7`9 and of genetic AA amyloidosis in the duck."0 Therapeutic trials on a small number of patients indicated that prolonged treatment with this agent may be effective in certain types of systemic amyloidosis.1113
The following report summarises our experience of prolonged DMSO treatment in 13 patients with systemic amyloidosis.
Patients and methods
The trial included 13 patients with acquired systemic amyloidosis, 3 The laboratory results given in this table are the average of 3 determinations done on 3 subsequent days.
'Per. =plasma creatinine.
For other abbreviations see Table 1 .
group.bmj.com on June 22, 2017 -Published by http://ard.bmj.com/ Downloaded from D-penicillamine. One patient was nephrotic with preserved renal function, and 2 had renal failure. During the first 10 months of oral DMSO treatment (15 g/day) some improvement of renal function was observed in all 3 patients, manifested by a decline in proteinuria, a modest rise of serum albumin, and an increase of creatinine clearance in the 2 patients in whom it had been initially impaired (Table 2) . From the 11th month onwards the DMSO was given on alternate days and the dose was reduced to 10 g/day.
Patient 5 was seen only once on a follow-up visit 4 months later. The renal functions were stable: creatinine 2-3 mg/dl (203 gmol/l), blood urea 57 mg/dl (9 5 mmolIl), albumin 3-4 g/dl (34 g/l), proteinuria 2 (Fig. 3) . The patient then d an acute pulmonary infection and died in respiratory failure. Permission for necropsy was refused.
Patient 10, a male aged 46, had amyloidosis secondary to ankylosing spondylitis which had been diagnosed at the age of 21. Seven months of oral DMSO (10 g/day) helped to reduce the blood urea from 150 to 60 mg/dl (25-10 mmolI) and double the creatinine clearance from 18 to 35 mUmin. The patient has remained stable for 2 years and is maintained on DMSO now reduced to 6 g/day taken at bedtime and alternating with nonsteroid anti-inflammatory drugs (Fig. 4) Three series of patients with amyloidosis treated with DMSO have thus far been reported."'3 Out of 17 patients with myeloma-associated amyloidosis reported by Osserman, Sherman, and Kyle1' only 8 patients received DMSO for periods longer than 6 months, and 6 of them showed some clinical improvement in terms of regression of macroglossia, decrease in liver size, and regression of neuropathy. However, all those patients were concomitantly treated with melphalan. A potentiation of melphalan effect by DMSO could thus be postulated, and these results cannot be interpreted as demonstrating an unequivocal therapeutic effect of DMSO on myeloma-associated amyloidosis. Two patients with myeloma-associated amyloidosis were included in the series reported by Van Rijswijk etal.12 The results of DMSO were inconclusive. The only patients who responded to DMSO in that series were 3 with amyloidosis secondary to rheumatoid arthritis.
The present report includes 13 patients of whom 7 showed a significant clinical response to prolonged DMSO administration. These patients had systemic amyloidosis secondary to systemic inflammatory or chronic infectious diseases. An increase of creatinine clearance, a decline in proteinuria, and regression of all parameters of the nephrotic syndrome were evident after 3-5 months of continuous treatment. 
